Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

Study ID
NCT01968213

Study type
Interventional

Study phase
Phase 3

Study status
Completed

Trial Acronym

ARIEL3

Trial Summary

Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus placebo. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

More informations

Trial Starting Date

Apr 07,2014

Requirements

Gender Female
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

564